Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.325    0.00 (0.00%)
Bid:
1.25
Ask:
1.40
Spread: 0.15 (12.00%)
Market Cap: £21.27m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Director/PDMR Shareholding

18 Jul 2019 07:00

RNS Number : 9066F
Genedrive PLC
18 July 2019
 

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them

 

genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that Dr Ian Gilham, Non-Executive Chairman, acquired 51,250 ordinary shares of 1.5p each ("Ordinary Shares") in the Company at an average price of 19p per share.

 

Following these purchases, Dr Gilham is interested in 317,674 Ordinary Shares, 0.93% of the issued share capital of the Company.

 

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Ian Gilham

 

 

2.

Reason for the notification

a.

Position/status

Non-Executive Chairman

a.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

genedrive plc

b.

LEI

213800ZYODIRZ87Y4K14

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type

of instrument

Identification code

Ordinary shares of 1.5 pence each

b.

Nature of the transaction

Purchase

c.

Price(s) and volume(s)

 

Price(s)

Volume(s)

19p

51,250

 

d.

Aggregated information

· Aggregated volume

· Price

 

 

N/A

 

e.

Date of the transaction

2019-07-17; UTC time

f.

Place of the transaction

London Stock Exchange, AIM

 

For further details please contact:

genedrive plc

+44 (0)161 989 0245

David Budd: CEO

 

Matthew Fowler: CFO

 

Peel Hunt LLP

+44 (0)207 418 8900

James Steel

 

Oliver Jackson

 

 

Stanford Capital Partners Limited

 

+44 (0)20 3815 8880

 

Patrick Claridge / John Howes

 

 

 

Walbrook PR Ltd (Media Relations & Investor Relations)

 

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHEAEXXFSSNEAF
Date   Source Headline
20th May 20203:38 pmRNSHolding(s) in Company
13th May 202010:26 amRNSHolding(s) in Company
12th May 20207:00 amRNSResults of Broker Option
7th May 20205:25 pmRNSHolding(s) in Company
7th May 20204:58 pmRNSPosting of shareholder circular
7th May 202011:05 amRNSSecond Price Monitoring Extn
7th May 202011:00 amRNSPrice Monitoring Extension
5th May 20206:24 pmRNSResult of Placing
5th May 20209:00 amRNSPrice Monitoring Extension
5th May 20208:50 amRNSProposed Placing and Broker Option
4th May 20205:00 pmRNSWHO Prequalification for Genedrive HCV-ID test
4th May 20202:05 pmRNSSecond Price Monitoring Extn
4th May 20202:00 pmRNSPrice Monitoring Extension
1st May 20202:05 pmRNSSecond Price Monitoring Extn
1st May 20202:01 pmRNSPrice Monitoring Extension
1st May 20207:00 amRNSManufacturing milestones met for SARS-CoV-2 test
29th Apr 20209:06 amRNSSecond Price Monitoring Extn
29th Apr 20209:00 amRNSPrice Monitoring Extension
28th Apr 20204:42 pmRNSSecond Price Monitoring Extn
28th Apr 20204:35 pmRNSPrice Monitoring Extension
28th Apr 20202:05 pmRNSSecond Price Monitoring Extn
28th Apr 20202:00 pmRNSPrice Monitoring Extension
27th Apr 20209:00 amRNSPrice Monitoring Extension
24th Apr 20203:30 pmRNSHolding(s) in Company
24th Apr 20207:00 amRNSDistribution agreement for AIHL test
24th Apr 20207:00 amRNSDistribution agreement for AIHL test
22nd Apr 20207:00 amRNSAppointment of Joint Broker
21st Apr 20204:41 pmRNSSecond Price Monitoring Extn
21st Apr 20204:36 pmRNSPrice Monitoring Extension
21st Apr 20202:52 pmRNSHolding(s) in Company
20th Apr 20209:05 amRNSSecond Price Monitoring Extn
20th Apr 20209:00 amRNSPrice Monitoring Extension
20th Apr 20207:00 amRNSCytiva collaboration on Coronavirus PCR Test
17th Apr 20202:06 pmRNSSecond Price Monitoring Extn
17th Apr 20202:01 pmRNSPrice Monitoring Extension
16th Apr 20202:53 pmRNSHolding(s) in Company
15th Apr 20204:41 pmRNSSecond Price Monitoring Extn
15th Apr 20204:36 pmRNSPrice Monitoring Extension
15th Apr 20202:05 pmRNSSecond Price Monitoring Extn
15th Apr 20202:00 pmRNSPrice Monitoring Extension
15th Apr 202011:05 amRNSSecond Price Monitoring Extn
15th Apr 202011:00 amRNSPrice Monitoring Extension
14th Apr 20209:06 amRNSSecond Price Monitoring Extn
14th Apr 20209:00 amRNSPrice Monitoring Extension
14th Apr 20207:01 amRNSHolding(s) in Company
14th Apr 20207:00 amRNSHolding(s) in Company
31st Mar 202011:52 amRNSHolding(s) in Company
30th Mar 20202:01 pmRNSHolding(s) in Company
30th Mar 202011:06 amRNSSecond Price Monitoring Extn
30th Mar 202011:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.